Stock comparison
Catalyst Pharmaceuticals
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CPRX
Catalyst Pharmaceuticals
Market cap
$3.83B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Catalyst Pharmaceuticals CPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CPRX | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 69C | 65C | CPRX |
| Benjamin Graham | 75B | 64C | CPRX |
| Philip Fisher | 87C | 48D | CPRX |
| Peter Lynch | 65B | 25F | CPRX |
| Joel Greenblatt | 42D | 76B | GMAB |
| Charlie Munger | 78B | 68C | CPRX |
| Terry Smith | 78B | 71C | CPRX |
Side-by-side metrics
| Metric | CPRX | GMAB |
|---|---|---|
| Market cap | $3.83B | $16.5B |
| P/E (TTM) | 17.3x | 6.2x |
| EV/EBIT | 11.9x | 12.0x |
| ROIC (TTM) | 19.67% | 43.78% |
| Gross margin | 82.32% | 93.88% |
| Net margin | 37.08% | 18.23% |
| Revenue CAGR 5y | 43.0% | -18.45% |
| EPS CAGR 5y | 46.49% | -23.48% |
| Debt / Equity | 0.0x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CPRX leads on
- EPS CAGR 5y46.49%vs -23.48%+150%
- Revenue CAGR 5y43.0%vs -18.45%+143%
- Debt / Equity0.0xvs 0.1x+96%
- Net margin37.08%vs 18.23%+51%
GMAB leads on
- Market cap$16.5Bvs $3.83B+77%
- P/E (TTM)6.2xvs 17.3x+64%
- ROIC (TTM)43.78%vs 19.67%+55%
- Gross margin93.88%vs 82.32%+12%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.